JPRN-UMIN000005636已完成2 期
Phase II study of a full-dose THP-COP regimen for aggressive non-Hodgkin lymphoma in the elderly - THP-1
Hematological Malignancy Clinical Study Group0 个研究点目标入组 30 人开始时间: 2011年5月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with any other malignancies 2)mental illness 3)a history of myocardial infarction or angina 4)central nervous system infiltration 5)uncontrollable diabetes 6)human immunodeficiency virus infection 7) hepatitis B virus surface antigen 8)hepatitis C virus antibody positivity
研究者
相似试验
招募中
2 期
Phase II trial of biweekly THP-COP therapy for patients with peripheral T-cell lymphomas.Peripheral T-cell lymphomas (PTCL,nos, AITL, ALK-negative ALCL)JPRN-UMIN000018919Kanagawa Clinical Oncology study Group40
招募中
2 期
The randomized controlled trial of the THP-COP therapy versus CHOP therapy for T-cell lymphoma with or without P-glycoprotein expressioT cell LymphomaJPRN-UMIN000004092Osaka Lymphoma Study Group94
已完成
2 期
The randomized controlled trial of the R-THP-COP therapy (14 days) versus R-CHOP therapy (14 days) for treatment of patients under the age of 70 with untreated advanced stage diffuse large B-cell lymphoma, Phase II and III studydiffuse large B-cell lymphomaJPRN-UMIN000007283Gifu University Hospital80
已完成
2 期
The randomized controlled trial of the R-THP-COP therapy versus R-CHOP therapy for treatment of elderly patients with untreated advanced stage diffuse large B-cell lymphoma, Phase II and III studydiffuse large B-cell lymphomaJPRN-UMIN000007282Gifu University Hospital70
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDsevere sepsisMedDRA version: 8.1Level: LLTClassification code 10040047Term: SepsisEUCTR2006-002112-99-BEEli Lilly & Company Limited488